References
1. Yang, S., Tsiatis, A. A. & Blazing, M. Modeling survival distribution as a function of time to treatment discontinuation: A dynamic treatment regime approach.Biometrics 74, 900–909 (2018).
2. Gong, Y. et al. Time to treatment discontinuation (TTD) as a pragmatic endpoint in metastatic non-small cell lung cancer (mNSCLC): A pooled analysis of 8 trials.Journal of Clinical Oncology vol. 36 9064–9064 (2018).
3. Walker, M. S., Herms, L. & Miller, P. J. E. Performance of time to discontinuation and time to next treatment as proxy measures of progression-free survival, overall and by treatment group. Journal of Clinical Oncology vol. 38 e19135–e19135 (2020).
4. Ramakrishnan, K. et al. Real-world time on treatment with immuno-oncology therapy in recurrent/metastatic head and neck squamous cell carcinoma. Future Oncol. 17, 3037–3050 (2021).
5. Velcheti, V. et al.Real-World Time on Treatment with First-Line Pembrolizumab Monotherapy for Advanced NSCLC with PD-L1 Expression ≥ 50%: 3-Year Follow-Up Data.Cancers vol. 14 1041 (2022).
6. Weis, T. M., Hough, S., Reddy, H. G., Daignault-Newton, S. & Kalemkerian, G. P. Real-world comparison of immune checkpoint inhibitors in non-small cell lung cancer following platinum-based chemotherapy. J. Oncol. Pharm. Pract.26, 564–571 (2020).
7. Bauml, J. et al.Pembrolizumab for Platinum- and Cetuximab-Refractory Head and Neck Cancer: Results From a Single-Arm, Phase II Study. J. Clin. Oncol. 35, 1542–1549 (2017).
8. Blumenthal, G. M. et al. Analysis of time-to-treatment discontinuation of targeted therapy, immunotherapy, and chemotherapy in clinical trials of patients with non-small-cell lung cancer. Ann. Oncol. 30, 830–838 (2019).
9. Stewart, M. et al.An Exploratory Analysis of Real-World End Points for Assessing Outcomes Among Immunotherapy-Treated Patients With Advanced Non-Small-Cell Lung Cancer. JCO Clin Cancer Inform 3, 1–15 (2019).
10. Royston, P. & Parmar, M. K. B. Restricted mean survival time: an alternative to the hazard ratio for the design and analysis of randomized trials with a time-to-event outcome. BMC Medical Research Methodology vol. 13 (2013).
11. Lopes, G. et al.Pembrolizumab (pembro) versus platinum-based chemotherapy (chemo) as first-line therapy for advanced/metastatic NSCLC with a PD-L1 tumor proportion score (TPS) ≥ 1%: Open-label, phase 3 KEYNOTE-042 study.Journal of Clinical Oncology vol. 36 LBA4–LBA4 (2018).
12. Argiris, A. & Johnson, J. Faculty Opinions recommendation of Pembrolizumab for Platinum- and Cetuximab-Refractory Head and Neck Cancer: Results From a Single-Arm, Phase II Study. Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature (2017) doi:10.3410/f.727429341.793534852.
13. Kaplan, E. L. & Meier, P. Nonparametric Estimation from Incomplete Observations. Springer Series in Statistics 319–337 (1992) doi:10.1007/978-1-4612-4380-9_25.
14. Guan, Y. et al. A survival model generalized to regression learning algorithms. Nat Comput Sci 1, 433–440 (2021).
15. Suthaharan, S. Support Vector Machine. Machine Learning Models and Algorithms for Big Data Classification 207–235 (2016) doi:10.1007/978-1-4899-7641-3_9.
16. Flatiron Health.Flatiron Health https://flatiron.com/ (2017).